8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Alvin Reilly
8.9
- - Regulatory Submission
- - 6 weeks February 2023
- - Biotech Startup
Reviewed:
Professional and knowledgeable, seamless regulatory submission process.
Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.
Traci Gulgowski
8.6
- - Patient Engagement
- - 8 weeks August - September 2023
- - Clinical Research Organization
Reviewed:
Impressive patient engagement strategies, significant improvement in recruitment rates.
The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.
Merle Nicolas
9.5
- - Gene Therapy Development
- - 12 weeks January - March 2023
- - Research Institution
Reviewed:
Innovative approach to gene therapy development, collaborative team.
The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.
Abel Considine
9
- - Process Development
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Expert process development, enhanced efficiency.
The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.
Rick McCullough
5.7
- - Project Management
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Poor communication and missed deadlines caused frustration.
Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.
Dexter Gleason MD
9.1
- - HTA Submission
- - 8 weeks February - March 2024
- - Biotech Company
Reviewed:
Comprehensive and well-executed HTA submission.
The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.
Hugo Turner
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
Andrea Stroman
6.5
- - Regulatory Submission
- - 8 weeks May - July 2024
- - Pharmaceutical Company
Reviewed:
Regulatory submission was incomplete, required additional work.
The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.
